Y Intercept Hong Kong Ltd Purchases New Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Key Points

• Y Intercept Hong Kong Ltd has acquired a new stake in Charles River Laboratories International, purchasing 3,760 shares valued at approximately $566,000.
• Multiple large investors have increased their stakes in Charles River Laboratories, with institutional investors now holding 98.91% of the company's stock.
• Analyst ratings for Charles River Laboratories vary, with some upgrades and downgrades leading to a consensus rating of "Hold" and an average target price of $174.54.

Y Intercept Hong Kong Ltd acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 3,760 shares of the medical research company's stock, valued at approximately $566,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Rothschild Investment LLC lifted its holdings in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after acquiring an additional 144 shares during the last quarter. HM Payson & Co. purchased a new stake in shares of Charles River Laboratories International in the first quarter valued at about $31,000. Optiver Holding B.V. acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $37,000. GeoWealth Management LLC raised its holdings in Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after acquiring an additional 190 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International in the fourth quarter valued at approximately $48,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded down $3.08 on Thursday, hitting $173.11. The company's stock had a trading volume of 114,167 shares, compared to its average volume of 1,288,067. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The company has a 50-day simple moving average of $152.28 and a 200 day simple moving average of $149.95. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a market capitalization of $8.50 billion, a PE ratio of -266.47, a PEG ratio of 6.04 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The firm's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.27 earnings per share. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president directly owned 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a research report on Wednesday, May 14th. Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Barclays raised their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research note on Thursday, May 8th. Finally, Evercore ISI boosted their price objective on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $174.54.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).